DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Acitretin Plasma Levels Under Hemodialysis

Information source: University of Zurich
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Carcinoma, Squamous Cell

Intervention: Chemopreventive application (Acitretin) (Drug)

Phase: Phase 4

Status: Suspended

Sponsored by: GŁnther Hofbauer

Official(s) and/or principal investigator(s):
01 Studienregister MasterAdmins, Study Director, Affiliation: UniversitaetsSpital Zuerich

Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Clinical Details

Official title: Acitretin Plasma Levels Under Hemodialysis

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Plasma levels acitretin

Detailed description: Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined.

- Trial with medicinal product

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Hemodialyis patients with at least one case of in-situ or invasive squamous cell

carcinoma of the skin Exclusion criteria:

- Hepatopathy

- Pregnancy

Locations and Contacts

Clinic for Dermatology University Hospital of Zurich, Zurich, Switzerland
Additional Information

Starting date: June 2007
Last updated: June 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015